Novadiscovery, a French pioneer in the use of in silico clinical trials to predict drug efficacy and optimize clinical development, has raised five million euros ($6 million) in a Series A financing. 9 January 2020
In recent years, digital transformation has gone from being a promise to a reality, writes Francesca Domenech Wuttke, Chief Digital Officer, Almirall. 2 December 2019
Given that they have a certain luxury for blue sky thinking and the capacity to lead rather than react to industry and societal trends, for big pharma companies to have highly ambitious digital strategies is not unusual. 28 November 2019
Swedish drug developer Orexo today announced it has acquired the exclusive US rights to vorvida, a digital therapy for the treatment of alcohol use disorder (AUD), from GAIA AG, a global leader in digital therapeutics. 27 November 2019
Anglo-Swedish pharma major AstraZeneca’s love affair with China shows no sign of cooling off, with the company now announcing three new projects in the Asian country to advance its R&D efforts. 6 November 2019
Google and other search engines are putting consumers at risk of buying fake pharmaceutical products by refusing to remove these websites in their search results. 22 October 2019
China is currently the second largest pharmaceutical market in the world and is aiming to be a major innovator as well, as part of its ‘Made in China 2025’ program. 14 October 2019
Hong Kong-based Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program AI drug discovery collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceutical (CTFH), taking on previously undruggable targets. 9 October 2019
A new research collaboration between Danish diabetes giant Novo Nordisk and the Cambridge, USA-based firm bluebird bio will see the companies work together on certain in vivo gene editing technologies. 9 October 2019
Swiss pharma giant Novartis has launched a new digital collaboration with Microsoft, a software company, aimed at boosting the firm’s artificial intelligence capabilities. 1 October 2019
BenevolentAI, a UK artificial intelligence (AI) company focused on health and drug development, has announced a new collaboration, with Swiss giant Novartis. 6 September 2019
Pharma and other health companies are buying big into the artificial intelligence (AI) space, and the UK’s Health Secretary has now given this technology a major vote of confidence too. 8 August 2019
A company that calls itself the world-leading AI-driven drug discovery company has entered into a collaboration with Rallybio, a privately-held development-stage biotechnology company focused on rare diseases. 23 July 2019
IBM Watson Health has seen that being thought of as a pioneering company in applying artificial intelligence (AI) in healthcare can have its pros and cons, from a publicity point of view. 2 July 2019
Merck & Co is to participate in a US Food and Drug Administration (FDA) pilot program that uses blockchain technology to improve the way medicines are identified, tracked and traced within the USA. 13 June 2019
The life sciences arm of Google-parent company Alphabet, Verily, has announced that four of the world’s leading pharma companies have joined its Project Baseline initiative. 22 May 2019
In a previous incarnation, Boehringer Ingelheim chief financial officer Michael Schmelmer spearheaded a bold approach to innovation which could bear digital fruit for the 130 year-old family-owned drugmaker. 10 May 2019
Californian companies Gilead Sciences and Genesis Therapeutics have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. 10 September 2024
ZipBio, a newly launched start-up based in Seattle, USA, is aiming to set a new standard in the development of biologics and gene therapies by utilizing generative AI technology. 9 September 2024
Otsuka Pharmaceuticals says that its subsidiaries Otsuka Precision Health, Inc. (OPH) and Click Therapeutics (Click) have launched Rejoyn (developed as CT-152). 19 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
The use of AI across all industries and sectors has been heralded as driving efficiency and accelerating innovation, with some experts even citing the technology as the biggest disruptor of our lifetime. 21 May 2024
At a cool $1 billion, the venture round secured by AI group Xaira ranks as the second-biggest raise in biotech history. In the drug discovery space, this financing is dwarfed only by Altos Lab’s $3 billion, amassed back in 2021. 14 May 2024
The world’s top 20 pharma companies spent $145 billion between them on R&D investments in 2022-23 - compared to the prior year’s $139 million - according to research from the professional services firm Deloitte. 29 April 2024